Accelovance and Linical signed a merger agreement

| By | Drug Development, R&D
0
247

Accelovance (USA), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine announced that it has signed a merger agreement with Linical (Japan), a leading CRO based in Asia in the fields of oncology, immunology, and neurology.

This union creates a market-leading contract research organization with significant global scale across North America, Europe, and Asia Pacific. Both organizations have a 13-year history as trusted partners to biopharmaceutical companies, providing comprehensive and flexible clinical development solutions.

The new company will offer clients even deeper oncology expertise, with combined scientific strength in both the early and late phases of clinical development. In addition, the company will provide significant leadership in many other therapeutic areas – for example, Linical’s experience in neurology and immunology, as well as Accelovance’s offerings in vaccines, dermatology, pain, women’s health, and nutrition. Together, the companies’ services cover the entire drug life cycle, offering clients a one-stop provider for drug development, clinical research, a patient-focused call center, medical affairs, and post-marketing services.

SOURCE: accelovance
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.